Background: Alcohol consumption is a potential trigger for inflammatory bowel disease (IBD) flare because of alcohol-induced oxidative stress and its deleterious effects on gut barrier function. Additionally, we have recently shown that alcohol consumption is associated with more symptoms in IBD. However, it is not known whether moderate daily alcohol consumption can modify IBD disease activity. To test what effects alcohol may have on patients with IBD, we evaluated the effect of moderate daily red wine for 1 week on two factors associated with recurrent IBD disease activity: intestinal permeability and stool calprotectin. Methods: To assess the effects of moderate daily alcohol consumption on intestinal permeability and inflammation, we recruited 21 patients: 8 with inactive ulcerative colitis (UC), 6 with inactive Crohn’s disease (CD), and 7 healthy controls. All participants with IBD completed a validated questionnaire on disease activity (Crohn’s disease activity index or ulcerative colitis clinical activity index), to confirm they had inactive disease. All subjects then underwent a baseline assessment that included a blood draw, urine collection after sugar challenge, and stool collection. Subjects then consumed 1–3 glasses of red wine a day for 1 week (approx. 0.4 g EtOH/kg), and repeated the three measures. Results: No subjects flared during the study. Moderate alcohol consumption did not significantly change either clinical disease activity scores or C-reactive protein. In contrast to healthy subjects, daily consumption of red wine significantly (1) decreased stool calprotectin in IBD subjects from baseline (p = 0.001) and (2) increased intestinal permeability as measured by urinary lactulose/mannitol excretion (marker of small bowel permeability) in CD (p = 0.028) or urinary sucralose secretion (marker of large bowel permeability) in UC (p = 0.012). Conclusions: One week of moderate consumption of red wine in inactive IBD was associated with a significant decrease in stool calprotectin and a significant increase in intestinal permeability. Our data suggests that patients with inactive IBD who drink red wine daily may be at an increased long-term risk for disease relapse.

1.
Molodecky NA, Kaplan GG: Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (NY) 2010;6:339–346.
2.
Cottone M, Rosselli M, Orlando A, et al: Smoking habits and recurrence in Crohn’s disease. Gastroenterology 1994;106:643–648.
[PubMed]
3.
Cosnes J, Beaugerie L, Carbonnel F, Gendre JP: Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology 2001;120:1093–1099.
[PubMed]
4.
Green JT, Rhodes J, Ragunath K, et al: Clinical status of ulcerative colitis in patients who smoke. Am J Gastroenterol 1998;93:1463–1467.
5.
Aldhous MC, Drummond HE, Anderson N, et al: Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol 2007;102:589–597.
[PubMed]
6.
Patel M, Keshavarzian A, Kottapalli V, Badie B, Winship D, Fields JZ: Human neutrophil functions are inhibited in vitro by clinically relevant ethanol concentrations. Alcohol Clin Exp Res 1996;20:275–283.
7.
Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267–276.
[PubMed]
8.
Bjarnason I, Peters TJ, Wise RJ: The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984;1:179–182.
[PubMed]
9.
Tang Y, Forsyth CB, Banan A, Fields JZ, Keshavarzian A: Oats supplementation prevents alcohol-induced gut leakiness in rats by preventing alcohol-induced oxidative tissue damage. J Pharmacol Exp Ther 2009;329:952–958.
10.
Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P: Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009;33:1836–1846.
[PubMed]
11.
Jowett SL, Seal CJ, Pearce MS, et al: Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004;53:1479–1484.
[PubMed]
12.
Hey H, Schmedes A, Nielsen AA, Winding P, Gronbaek H: Effects of five different alcoholic drinks on patients with Crohn’s disease. Scand J Gastroenterol 2007;42:968–972.
13.
Swanson GR, Sedghi S, Farhadi A, Keshavarzian A: Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol 2010;44:223–228.
14.
Wyatt J, Oberhuber G, Pongratz S, et al: Increased gastric and intestinal permeability in patients with Crohn’s disease. Am J Gastroenterol 1997;92:1891–1896.
15.
Arnott ID, Kingstone K, Ghosh S: Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000;35:1163–1169.
[PubMed]
16.
Wild GE, Waschke KA, Bitton A, Thomson AB: The mechanisms of prednisone inhibition of inflammation in Crohn’s disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther 2003;18:309–317.
17.
Gisbert JP, Bermejo F, Perez-Calle JL, et al: Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190–1198.
[PubMed]
18.
Sandborn WJ, Feagan BG, Hanauer SB, et al: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002;122:512–530.
[PubMed]
19.
Farhadi A, Keshavarzian A, Fields JZ, Sheikh M, Banan A: Resolution of common dietary sugars from probe sugars for test of intestinal permeability using capillary column gas chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2006;836:63–68.
20.
Farhadi A, Keshavarzian A, Holmes EW, Fields J, Zhang L, Banan A: Gas chromatographic method for detection of urinary sucralose: application to the assessment of intestinal permeability. J Chromatogr B Analyt Technol Biomed Life Sci 2003;784:145–154.
21.
Anderson AD, Poon P, Greenway GM, MacFie J: A simple method for the analysis of urinary sucralose for use in tests of intestinal permeability. Ann Clin Biochem 2005;42:224–226.
22.
Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426–431.
[PubMed]
23.
Sakamoto N, Kono S, Wakai K, et al: Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005;11:154–163.
24.
Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS: The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology 2006;131:410–419.
[PubMed]
25.
Keefer L, Stepanski EJ, Ranjbaran Z, Benson LM, Keshavarzian A: An initial report of sleep disturbance in inactive inflammatory bowel disease. J Clin Sleep Med 2006;2:409–416.
[PubMed]
26.
Reid MC, Fiellin DA, O’Connor PG: Hazardous and harmful alcohol consumption in primary care. Arch Intern Med 1999;159:1681–1689.
27.
Adams PF, Schoenborn CA: Health behaviors of adults: United States, 2002–04. Vital Health Stat 10 2006;230:1–140.
28.
Szabo G, Mandrekar P: A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res 2009;33:220–232.
29.
Bode C, Bode JC: Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol Clin Exp Res 2005;29:166S–171S.
[PubMed]
30.
Lakatos PL, Kiss LS, Palatka K, et al: Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn’s disease. Inflamm Bowel Dis 2011;17:767–777.
31.
McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G: Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009;15:100–113.
[PubMed]
32.
Costa F, Mumolo MG, Ceccarelli L, et al: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005;54:364–368.
33.
Shah VO, Ferguson JE, Hunsaker LA, Deck LM, Vander Jagt DL: Natural products inhibit LPS-induced activation of pro-inflammatory cytokines in peripheral blood mononuclear cells. Nat Prod Res 2010;24:1177–1188.
34.
Yusuf N, Nasti TH, Meleth S, Elmets CA: Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis. Mol Carcinog 2009;48:713–723.
35.
Montalto M, Gallo A, Ferrulli A, et al: Fecal calprotectin concentrations in alcoholic patients: a longitudinal study. Eur J Gastroenterol Hepatol 2011;23:76–80.
36.
O’Keefe JH, Bybee KA, Lavie CJ: Alcohol and cardiovascular health: the razor-sharp double-edged sword. J Am Coll Cardiol 2007;50:1009–1014.
[PubMed]
You do not currently have access to this content.